Neupedix (Alprostadil)

Alprostadil acts as a prostaglandin E1 analog, binding to prostaglandin receptors on smooth muscle cells. This activates adenylate cyclase, raising intracellular cyclic AMP levels, which relaxes smooth muscle and causes vasodilation, thereby increasing blood flow to the penis, fetal ductus arteriosus, or peripheral limbs.

The specific dose of Neupedix is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Healthcare professionals calculate the appropriate intravenous amount and infusion rate according to established clinical guidelines.

Safety data for alprostadil in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by a qualified healthcare provider. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Neupedix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Neupedix (alprostadil) is a prostaglandin‑based vasodilator administered intravenously, whereas many alternatives, such as sildenafil, are oral phosphodiesterase‑5 inhibitors. Alprostadil directly relaxes penile smooth muscle, offering an option for patients who cannot take oral agents, but it requires clinical administration and monitoring.

Neupedix should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Neupedix is supplied as an injectable solution for intravenous use. A qualified healthcare professional prepares the dose according to the prescriber’s instructions and administers it via a controlled IV infusion, monitoring the patient for hemodynamic changes during and after the procedure.

The most serious risks include severe hypotension, priapism lasting more than four hours, and allergic reactions that can progress to anaphylaxis. Prompt medical attention is required if any of these events occur, and patients should be monitored closely during and after infusion.

Neupedix is contraindicated in patients with known hypersensitivity to alprostadil or any component of the formulation, those with severe uncontrolled hypertension, or individuals who have experienced priapism previously. Caution is also advised for patients taking nitrates or other potent vasodilators.